1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ezetimibe / Simvastatin Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 199 Wenhai North Road
           HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : powder
Colour : No data available
Odour : No data available

Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure. Harmful to aquatic life. Toxic to aquatic life with long lasting effects.

GHS Classification
Skin corrosion/irritation : Category 2
Skin sensitisation : Category 1
Specific target organ toxicity - repeated exposure : Category 1
Short-term (acute) aquatic hazard : Category 3
Long-term (chronic) aquatic hazard : Category 2

GHS label elements
Hazard pictograms :

Signal word : Danger
Hazard statements:
H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H372 Causes damage to organs through prolonged or repeated exposure.
H402 Harmful to aquatic life.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements:
Prevention:
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves.
Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P314 Get medical advice/attention if you feel unwell.
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.
P391 Collect spillage.
Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure.

Environmental hazards
Harmful to aquatic life. Toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>79902-63-9</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 -&lt; 10</td>
</tr>
</tbody>
</table>
4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Fluorine compounds
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Ezetimibe / Simvastatin Formulation

Version 5.5
Revision Date: 09/13/2019
SDS Number: 28115-00014
Date of last issue: 2019/04/24
Date of first issue: 2014/11/04

Special protective equipment for firefighters
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling
Technical measures
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation
- Use only with adequate ventilation.

Advice on safe handling
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact
- Oxidizing agents
**Storage**

- **Conditions for safe storage**: Keep in properly labelled containers. Store in accordance with the particular national regulations.

- **Materials to avoid**: Do not store with the following product types:
  - Strong oxidizing agents

- **Packaging material**: Unsuitable material: None known.

---

### 8. EXPOSURE CONTROLS/PERSOAL PROTECTION

#### Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>PC-TWA</td>
<td>10 mg/m³</td>
<td>GBZ 2.1-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>79902-63-9</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: DSEN</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable fraction)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable fraction)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

#### Engineering measures

- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
- Minimize open handling.

#### Personal protective equipment

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - **Filter type**: Particulates type
- **Eye/face protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available
10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
# Ezetimibe / Simvastatin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>09/13/2019</td>
<td>28115-00014</td>
<td>2019/04/24</td>
<td>2014/11/04</td>
</tr>
</tbody>
</table>

## Acute Inhalation Toxicity
- **Ezetimibe**:
  - LC50 (Rat): > 5.8 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

## Acute Dermal Toxicity
- **Ezetimibe**:
  - LD50 (Rabbit): > 2,000 mg/kg

## Acute Oral Toxicity
- **Ezetimibe**:
  - LD50 (Rat): > 5,000 mg/kg
  - LD50 (Mouse): > 5,000 mg/kg
  - LD50 (Dog): > 3,000 mg/kg

## Acute Inhalation Toxicity
- **Ezetimibe**:
  - Remarks: No data available

## Acute Dermal Toxicity
- **Ezetimibe**:
  - Remarks: No data available

## Acute Toxicity (other routes of administration)
- **Ezetimibe**:
  - LD50 (Rat): > 2,000 mg/kg
  - Application Route: Intraperitoneal
  - LD50 (Mouse): > 1,000 - < 2,000 mg/kg
  - Application Route: Intraperitoneal

## Acute Oral Toxicity
- **Simvastatin**:
  - LD50 (Rat): 5,000 mg/kg
  - LD50 (Mouse): 3,800 mg/kg

## Magnesium Stearate
- **Acute Oral Toxicity**:
  - LD50 (Rat): > 2,000 mg/kg
  - Method: OECD Test Guideline 423
  - Assessment: The substance or mixture has no acute oral toxicity
  - Remarks: Based on data from similar materials

## Acute Dermal Toxicity
- **Magnesium Stearate**:
  - LD50 (Rabbit): > 2,000 mg/kg
  - Remarks: Based on data from similar materials

## Skin Corrosion/Irritation
- Causes skin irritation.

### Components:

#### Ezetimibe:
- **Species**: Rabbit
- **Result**: No skin irritation

#### Simvastatin:
- **Species**: Rabbit
- **Remarks**: Moderate skin irritation
Magnesium stearate:
Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ezetimibe:
Species : Rabbit
Result : No eye irritation

Simvastatin:
Species : Rabbit
Remarks : slight irritation

Magnesium stearate:
Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation
May cause an allergic skin reaction.

Respiratory sensitisation
Not classified based on available information.

Components:

Ezetimibe:
Test Type : Maximisation Test
Species : Guinea pig
Result : negative

Simvastatin:
Assessment : Probability or evidence of skin sensitisation in humans
Result : positive

Magnesium stearate:
Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials
### Components:

#### Cellulose:

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

**Genotoxicity in vivo**
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

#### Ezetimibe:

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Metabolic activation: with and without metabolic activation
    - Result: negative
- Test Type: Chromosomal aberration
  - Test system: Human lymphocytes
  - Result: negative

**Genotoxicity in vivo**
- Test Type: Micronucleus test
  - Species: Mouse
  - Cell type: Bone marrow
  - Application Route: Oral
  - Result: negative

#### Simvastatin:

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Alkaline elution assay
  - Result: negative
- Test Type: Chromosomal aberration
  - Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

**Genotoxicity in vivo**
- Test Type: Micronucleus test
  - Species: Mouse
  - Application Route: Oral
  - Result: negative

### Germ cell mutagenicity

Not classified based on available information.

Germ cell mutagenicity - Assessment
- Weight of evidence does not support classification as a germ cell mutagen.
Magnesium stearate:
Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
  Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
  Method: OECD Test Guideline 473
  Result: negative
  Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
  Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Cellulose:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 72 weeks
- Result: negative

Ezetimibe:
- Species: Rat, female
- Application Route: oral (feed)
- Exposure time: 104 weeks
- Result: negative
- Species: Rat, male
- Application Route: oral (feed)
- Exposure time: 104 weeks
- Result: negative
- Species: Mouse
- Application Route: oral (feed)
- Exposure time: 104 weeks
- Result: negative

Simvastatin:
- Species: Mouse
- Application Route: Oral
- Exposure time: < 92 weeks
- Target Organs: Harderian gland
- Tumor Type: Liver, Lungs
- Remarks: The significance of these findings for humans is not certain.
- Species: Rat
Ezetimibe / Simvastatin Formulation

Application Route: Oral
Exposure time: 2 Years
Tumor Type: Liver, Thyroid
Remarks: The significance of these findings for humans is not certain.

Reproductive toxicity
Not classified based on available information.

Components:

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Ezetimibe:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1,000 mg/kg body weight
Result: No effects on fertility, No fetotoxicity

Effects on foetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects

Simvastatin:
Effects on fertility: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development
Ezetimibe / Simvastatin Formulation

Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight
Result: Teratogenic potential
Remarks: Based on data from similar materials

Magnesium stearate:
Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Causes damage to organs through prolonged or repeated exposure.

Components:

Simvastatin:
Target Organs : Liver, muscle, optic nerve, Eye
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:
Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Ezetimibe:
Species : Dog
### Ezetimibe / Simvastatin Formulation

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,000 mg/kg</td>
<td>Oral</td>
<td>90 d</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Species**: Rat  
**NOAEL**: 1,500 mg/kg  
**Application Route**: Oral  
**Exposure time**: 90 d  
**Remarks**: No significant adverse effects were reported

**Species**: Mouse  
**NOAEL**: 500 mg/kg  
**Application Route**: Oral  
**Exposure time**: 90 d  
**Remarks**: No significant adverse effects were reported

**Species**: Dog  
**NOAEL**: 300 mg/kg  
**Application Route**: Oral  
**Exposure time**: 1 yr  
**Remarks**: No significant adverse effects were reported

### Simvastatin:

**Species**: Rat  
**NOAEL**: 5 mg/kg  
**LOAEL**: 30 mg/kg  
**Application Route**: Oral  
**Exposure time**: 14 - 104 Weeks  
**Target Organs**: Liver, Testis, Musculo-skeletal system, Eye

**Species**: Dog  
**LOAEL**: 10 mg/kg  
**Application Route**: Oral  
**Exposure time**: 14 - 104 Weeks  
**Target Organs**: Liver, Testis, Eye

**Species**: Rabbit  
**NOAEL**: 30 mg/kg  
**LOAEL**: 50 mg/kg  
**Application Route**: Oral  
**Target Organs**: Liver, Kidney

### Magnesium stearate:

**Species**: Rat  
**NOAEL**: > 100 mg/kg  
**Application Route**: Ingestion  
**Exposure time**: 90 Days  
**Remarks**: Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.
Ezetimibe / Simvastatin Formulation

Components:

Ezetimibe:
Not applicable

Experience with human exposure

Components:

Ezetimibe:
Ingestion: Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Simvastatin:
Skin contact: Remarks: May produce an allergic reaction.
Ingestion: Target Organs: Liver
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea
Target Organs: Musculo-skeletal system

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Ezetimibe:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 1

Toxicity to microorganisms: EC50: > 4.4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Simvastatin:

Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 3.5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l
Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l
Exposure time: 96 h

Toxicity to microorganisms: EC50: > 30 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 21 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

**Persistence and degradability**

**Components:**

**Cellulose:**

Biodegradability: Result: Readily biodegradable.

**Ezetimibe:**

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 6.8 %
Exposure time: 28 d

Stability in water: Hydrolysis: 50 %(4.5 d)
Method: OECD Test Guideline 111

**Simvastatin:**
Biodegradability: Result: rapidly degradable
Stability in water: Hydrolysis: 50 % (3.2 d)

**Magnesium stearate:**
Biodegradability: Result: Not biodegradable
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

**Ezetimibe:**
Bioaccumulation:
Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: \( \log \text{Pow} = 4.36 \)

**Simvastatin:**
Partition coefficient: n-octanol/water: \( \log \text{Pow} > 4.07 \)

**Magnesium stearate:**
Partition coefficient: n-octanol/water: \( \log \text{Pow} > 4 \)

### Mobility in soil

#### Components:

**Ezetimibe:**
Distribution among environmental compartments: \( \log \text{Koc} = 4.35 \)
Method: OECD Test Guideline 106

### Other adverse effects

No data available

---

### 13. DISPOSAL CONSIDERATIONS

**Disposal methods**
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**
## SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

### Ezetimibe / Simvastatin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5</td>
<td>09/13/2019</td>
<td>28115-00014</td>
<td>2019/04/24</td>
<td>2014/11/04</td>
</tr>
</tbody>
</table>

- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)

#### IATA-DGR

- **UN/ID No.**: UN 3077
- **Proper shipping name**: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)

- **Class**: 9
- **Packing group**: III
- **Labels**: Miscellaneous
- **Packing instruction (cargo aircraft)**: 956
- **Packing instruction (passenger aircraft)**: 956
- **Environmentally hazardous**: yes

#### IMDG-Code

- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)

- **Class**: 9
- **Packing group**: III
- **Labels**: 9
- **EmS Code**: F-A, S-F
- **Marine pollutant**: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

### National Regulations

**GB 6944/12268**

- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)

- **Class**: 9
- **Packing group**: III
- **Labels**: 9

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 15. REGULATORY INFORMATION

**National regulatory information**

**Law on the Prevention and Control of Occupational Diseases**
The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

### 16. OTHER INFORMATION

**Further information**

Sources of key data used to compile the Safety Data Sheet:

Date format: yyyy/mm/dd

**Full text of other abbreviations**

- **ACGIH**: USA, ACGIH Threshold Limit Values (TLV)
- **GBZ 2.1-2007**: Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.

**ACGIH / TWA**: 8-hour, time-weighted average

**GBZ 2.1-2007 / PC-TWA**: Permissible concentration - time weighted average

**Additional abbreviations**

- **AICS** - Australian Inventory of Chemical Substances; **ANTT** - National Agency for Transport by Land of Brazil; **ASTM** - American Society for the Testing of Materials; **bw** - Body weight; **CMR** - Carcinogen, Mutagen or Reproductive Toxicant; **DIN** - Standard of the German Institute for Standardisation; **DSL** - Domestic Substances List (Canada); **EcX** - Concentration associated with x% response; **ELx** - Loading rate associated with x% response; **EmS** - Emergency Schedule; **ENCS** - Existing and New Chemical Substances (Japan); **ErCx** - Concentration associated with x% growth rate response; **ERG** - Emergency Response Guide; **GHS** - Globally Harmonized System; **GLP** - Good Laboratory Practice; **IARC** - International Agency for Research on Cancer; **IATA** - International Air Transport Association; **IBC** - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; **IC50** - Half maximal inhibitory concentration; **ICAO** - International Civil Aviation Organization; **IECSC** - Inventory of Existing Chemical Substances in China; **IMDG** - International Maritime Dangerous Goods; **IMO** - International Maritime Organization; **ISHL** - Industrial Safety and Health Law (Japan); **ISO** - International Organisation for Standardization; **KECI** - Korea Existing Chemicals Inventory; **LC50** - Lethal Concentration to 50% of a test population; **LD50** - Lethal Dose to 50% of a test population (Median Lethal Dose); **MARPOL** - International Convention for the Prevention of Pollution from Ships; **n.o.s.** - Not Otherwise Specified; **Nch** - Chilean Norm; **NO(A)EC** - No Observed (Adverse) Effect Concentration; **NO(A)EL** - No Observed (Adverse) Effect Level; **NOELR** - No Observable Effect Loading Rate; **NOM** - Official Mexican Norm; **NTP** - National Toxicology Program; **NZIoC** - New Zealand Inventory of Chemicals; **OECD** - Organisation for Economic Co-operation and Development; **OPPTS** - Office of Chemical Safety and Pollution Prevention; **PBT** - Persistent, Bioaccumulative and Toxic substance; **PICCS** - Philippines Inventory of Chemicals and Chemical Substances; **(Q)SAR** - (Quantitative) Structure Activity Relationship; **REACH** - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; **SADT** - Self-Accelerating Decomposition Temperature; **SDS** - Safety Data Sheet; **TCSI** - Taiwan Chemical Substance Inventory; **TDG** - Trans-
Ezetimibe / Simvastatin Formulation

Version: 5.5
Revision Date: 09/13/2019
SDS Number: 28115-00014
Date of last issue: 2019/04/24
Date of first issue: 2014/11/04

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN